Ameriprise’s CRISPR Therapeutics CRSP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $13.7M | Sell |
250,614
-36,225
| -13% | -$1.91M | ﹤0.01% | 1813 |
|
|
2026
Q1 | $13.6M | Sell |
286,839
-10,405
| -4% | -$549K | ﹤0.01% | 1688 |
|
|
2025
Q4 | $15.6M | Sell |
297,244
-14,619
| -5% | -$876K | ﹤0.01% | 1594 |
|
|
2025
Q3 | $20.3M | Buy |
311,863
+49,774
| +19% | +$2.86M | ﹤0.01% | 1388 |
|
|
2025
Q2 | $12.7M | Buy |
262,089
+44,029
| +20% | +$1.7M | ﹤0.01% | 1641 |
|
|
2025
Q1 | $7.42M | Buy |
218,060
+12,887
| +6% | +$546K | ﹤0.01% | 1991 |
|
|
2024
Q4 | $8.07M | Buy |
205,173
+18,412
| +10% | +$869K | ﹤0.01% | 1977 |
|
|
2024
Q3 | $8.77M | Buy |
186,761
+23,884
| +15% | +$1.21M | ﹤0.01% | 1912 |
|
|
2024
Q2 | $8.8M | Buy |
162,877
+6,096
| +4% | +$353K | ﹤0.01% | 1857 |
|
|
2024
Q1 | $10.7M | Buy |
156,781
+28,887
| +23% | +$2.07M | ﹤0.01% | 1723 |
|
|
2023
Q4 | $8M | Buy |
127,894
+12,520
| +11% | +$692K | ﹤0.01% | 1980 |
|
|
2023
Q3 | $5.23M | Sell |
115,374
-13,945
| -11% | -$720K | ﹤0.01% | 2247 |
|
|
2023
Q2 | $7.26M | Buy |
129,319
+45,941
| +55% | +$2.61M | ﹤0.01% | 2055 |
|
|
2023
Q1 | $3.77M | Buy |
83,378
+25,994
| +45% | +$1.26M | ﹤0.01% | 2506 |
|
|
2022
Q4 | $2.33M | Sell |
57,384
-46,985
| -45% | -$2.49M | ﹤0.01% | 2742 |
|
|
2022
Q3 | $6.89M | Buy |
104,369
+45,237
| +77% | +$3.28M | ﹤0.01% | 1989 |
|
|
2022
Q2 | $3.59M | Buy |
59,132
+5,296
| +10% | +$311K | ﹤0.01% | 2511 |
|
|
2022
Q1 | $3.38M | Buy |
53,836
+7,909
| +17% | +$497K | ﹤0.01% | 2666 |
|
|
2021
Q4 | $3.48M | Sell |
45,927
-290,766
| -86% | -$25.4M | ﹤0.01% | 2701 |
|
|
2021
Q3 | $37.7M | Sell |
336,693
-77
| -0% | -$9.67K | 0.01% | 889 |
|
|
2021
Q2 | $54.5M | Sell |
336,770
-129,522
| -28% | -$15.8M | 0.02% | 760 |
|
|
2021
Q1 | $56.8M | Buy |
466,292
+17,396
| +4% | +$2.63M | 0.02% | 721 |
|
|
2020
Q4 | $68.5M | Sell |
448,896
-181,267
| -29% | -$21.4M | 0.02% | 602 |
|
|
2020
Q3 | $52.6M | Sell |
630,163
-436,415
| -41% | -$38.7M | 0.02% | 619 |
|
|
2020
Q2 | $78.4M | Buy |
1,066,578
+250,371
| +31% | +$14.6M | 0.03% | 464 |
|
|
2020
Q1 | $34.6M | Buy |
816,207
+346,434
| +74% | +$17.9M | 0.02% | 677 |
|
|
2019
Q4 | $28.6M | Buy |
469,773
+449,202
| +2,184% | +$24.5M | 0.01% | 959 |
|
|
2019
Q3 | $843K | Sell |
20,571
-37
| -0.2% | -$1.77K | ﹤0.01% | 3089 |
|
|
2019
Q2 | $971K | Sell |
20,608
-3,279
| -14% | -$131K | ﹤0.01% | 3080 |
|
|
2019
Q1 | $853K | Buy |
23,887
+1,214
| +5% | +$42K | ﹤0.01% | 3099 |
|
|
2018
Q4 | $648K | Sell |
22,673
-25,827
| -53% | -$898K | ﹤0.01% | 3107 |
|
|
2018
Q3 | $2.15M | Sell |
48,500
-3,902
| -7% | -$204K | ﹤0.01% | 2792 |
|
|
2018
Q2 | $2.99M | Buy |
52,402
+25,269
| +93% | +$1.44M | ﹤0.01% | 2549 |
|
|
2018
Q1 | $1.17M | Buy |
+27,133
| New | +$1.12M | ﹤0.01% | 2911 |
|
Other funds holding CRSP
AIM
OAG
GP
SOCM
Ameriprise's CRSP Position: Q2 2026 in Review
Ameriprise reduced its CRISPR Therapeutics (CRSP) stake by 13% in Q2 2026, selling an estimated $1.91M and leaving 250,614 shares worth $13.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1813.
Ameriprise first reported a position in CRSP in Q1 2018 and has held it in 34 quarters since. The position peaked at $78.4M in Q2 2020. 522 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.
- Ameriprise held 250,614 shares of CRISPR Therapeutics worth $13.7M as of Q2 2026.
- Ameriprise sold 36,225 CRISPR Therapeutics shares in Q2 2026, an estimated $1.91M.
- CRISPR Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #1813 holding.
- Ameriprise first reported a position in CRISPR Therapeutics in Q1 2018 and has held it in 34 quarters since.
- Ameriprise's CRISPR Therapeutics position peaked at $78.4M in Q2 2020.
- 522 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.
Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.